The role of the liver and kidneys in the pharmacokinetics of subcutaneously administered teriparatide acetate in rats.
Teriparatide acetate, a synthetic polypeptide fragment consisting of human parathyroid hormone residues 1-34 [hPTH(1-34)], is a bone anabolic agent used to treat osteoporosis.        The present study was conducted to characterise the pharmacokinetics of teriparatide acetate in rats after subcutaneous administration.        Teriparatide was rapidly absorbed into the circulation and eliminated immediately. No intact teriparatide was detected in the urine. To elucidate the mechanism of teriparatide metabolism, we performed in vivo and in vitro studies using the radiolabelled bioactive analogue, [(125)I]-[Nle(8,18),Tyr(34)]-hPTH(1-34). After subcutaneous administration, the concentration of analogue metabolites increased in the plasma time-dependently. The concentration in the kidneys was more than 3-fold the concentration in the liver. In vitro analyses suggested that kidney radioactivity was associated with degraded bioactive analogue. In model rats, renal failure, but not hepatic failure, affected the pharmacokinetics of teriparatide acetate, which accounted for the decrease in the clearance of teriparatide.        In conclusion, our results suggest that after subcutaneous administration of teriparatide acetate, teriparatide is rapidly absorbed and distributed to the liver or kidneys, where it is immediately degraded. The kidneys play a particularly important role in the distribution and metabolism of teriparatide, but not its excretion.
Laboratory for Safety Assessment & ADME, Pharmaceuticals Research Center, Asahi Kasei Pharma Corporation, Shizuoka, Japan. serada.mb@om.asahi-kasei.co.jp
Masashi
M
Serada
Aki
A
Sakurai-Tanikawa
Masayo
M
Igarashi
Koichi
K
Mitsugi
Toshie
T
Takano
Koichi
K
Shibusawa
Terutomo
T
Kohira
D000818:Animals; D002478:Cells, Cultured; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D007668:Kidney / Q000378:metabolism*; D008099:Liver / Q000378:metabolism*; D008297:Male; D010281:Parathyroid Hormone / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D019379:Teriparatide / Q000008:administration & dosage / Q000493:pharmacokinetics*
D010281:Parathyroid Hormone; D019379:Teriparatide